Amicogen Inc - Asset Resilience Ratio
Amicogen Inc (092040) has an Asset Resilience Ratio of 0.50% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Amicogen Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Amicogen Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 092040 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Amicogen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Amicogen Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.07 Billion | 0.5% |
| Total Liquid Assets | ₩1.07 Billion | 0.50% |
Asset Resilience Insights
- Limited Liquidity: Amicogen Inc maintains only 0.50% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Amicogen Inc Industry Peers by Asset Resilience Ratio
Compare Amicogen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Amicogen Inc (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Amicogen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.43% | ₩1.00 Billion ≈ $679.59K |
₩231.86 Billion ≈ $157.13 Million |
-2.64pp |
| 2024-12-31 | 3.07% | ₩9.03 Billion ≈ $6.12 Million |
₩294.23 Billion ≈ $199.39 Million |
-5.18pp |
| 2023-12-31 | 8.25% | ₩38.54 Billion ≈ $26.12 Million |
₩467.10 Billion ≈ $316.55 Million |
+2.74pp |
| 2022-12-31 | 5.51% | ₩23.68 Billion ≈ $16.05 Million |
₩429.65 Billion ≈ $291.17 Million |
-4.83pp |
| 2021-12-31 | 10.34% | ₩42.52 Billion ≈ $28.81 Million |
₩411.22 Billion ≈ $278.68 Million |
-5.19pp |
| 2020-12-31 | 15.53% | ₩43.99 Billion ≈ $29.81 Million |
₩283.37 Billion ≈ $192.03 Million |
+4.56pp |
| 2019-12-31 | 10.97% | ₩26.47 Billion ≈ $17.94 Million |
₩241.40 Billion ≈ $163.59 Million |
+4.57pp |
| 2018-12-31 | 6.40% | ₩14.79 Billion ≈ $10.02 Million |
₩231.21 Billion ≈ $156.69 Million |
-7.19pp |
| 2017-12-31 | 13.58% | ₩22.21 Billion ≈ $15.05 Million |
₩163.51 Billion ≈ $110.81 Million |
+3.86pp |
| 2016-12-31 | 9.73% | ₩14.23 Billion ≈ $9.65 Million |
₩146.33 Billion ≈ $99.17 Million |
+3.00pp |
| 2015-12-31 | 6.73% | ₩10.76 Billion ≈ $7.29 Million |
₩159.84 Billion ≈ $108.32 Million |
-2.67pp |
| 2014-12-31 | 9.40% | ₩5.11 Billion ≈ $3.46 Million |
₩54.37 Billion ≈ $36.84 Million |
-- |
About Amicogen Inc
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company o… Read more